TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01073293

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V503 Vaccine
Description: V503 (Multivalent HPV L1 VLP vaccine) given as a 0.5 mL intramuscular injection at Day 1, Month 2, and Month 6

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V503 Vaccine
Description: V503 (Multivalent HPV L1 VLP vaccine) given as a 0.5 mL intramuscular injection at Day 1, Month 2, and Month 6

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: REPEVAX™ (Concomitant)
Description: REPEVAX™ given as a single 0.5 mL intramuscular injection at Day 1

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: REPEVAX™ (Non-concomitant)
Description: REPEVAX™ given as a single 0.5 mL intramuscular injection at Month 1
Study: NCT03910595

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mepitel Film
Description: Mepitel film is a barrier film that may help in reducing radiation dermatitis by limiting friction.
Study: NCT01514357

Intervention type: DRUG
Group type: OTHER
Intervention: Nesiritide (BNP)
Description: NATRECOR® (nesiritide) is a sterile, purified preparation of human B-type natriuretic peptide (hBNP), and is manufactured from E. coli using recombinant DNA technology. Each 1.5 mg vial contains a white- to off-white lyophilized powder for intravenous (IV) administration after reconstitution.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered subcutaneously instead of active drug (nesiritide) in a blind fashion in the second arm of the study.
Study: NCT02966743

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: administration of midazolam during spinal anesthesia for target bispectral index 75-80

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: administration of dexmedetomidine during spinal anesthesia for target bispectral index 75-80
Study: NCT02137343

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rilotumumab
Description: Rilotumumab is a fully human monoclonal antibody immunoglobulin G, type 2 (IgG2) against human hepatocyte growth factor/scatter factor (HGF/SF) that blocks binding of HGF/SF to its receptor MET, inhibiting HGF/SF/MET-driven activities in cells.
Study: NCT02714127

Intervention type: OTHER
Intervention: First-void urine collection
Description: One time collection of ca. 20ml of first-void urine (i.e. the initial stream of the urine void) with the Colli-PeeTM device (Novosanis).

Intervention type: OTHER
Intervention: First-void urine collection
Description: One time collection of ca. 20ml of first-void urine (i.e. the initial stream of the urine void) with the Colli-PeeTM device (Novosanis).
Study: NCT02137343

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cisplatin
Description: A platinum containing chemo-therapy compound that reacts in vivo, binding to and causing crosslinking of DNA, which ultimately triggers apoptosis (programmed cell death)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: A platinum containing chemo-therapy compound that reacts in vivo, binding to and causing crosslinking of DNA, which ultimately triggers apoptosis (programmed cell death)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Capecitabine
Description: A chemo-therapy prodrug that is enzymatically converted to 5-fluorouracil in the tumor, where it inhibits DNA synthesis and slows growth of tumor tissue.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: A chemo-therapy prodrug that is enzymatically converted to 5-fluorouracil in the tumor, where it inhibits DNA synthesis and slows growth of tumor tissue.
Study: NCT04023045

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Assist-Knee
Description: Assist-Knee is an experimental lower limb knee prosthesis.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Habitual Prosthesis
Description: Habitual baseline prosthesis prescribed by participant's clinician.
Study: NCT02500108

Intervention type: DRUG
Intervention: Domperidone
Description: Current exposure to domperidone will be defined as a prescription dispensed within 30 days before the index date.~Recent exposure to domperidone will be defined as a prescription dispensed between 31 and 90 days before the index date (without a dispensing during the 30 days period preceding index date).~Past exposure to domperidone will be defined as a prescription dispensed between 91 and 365 days before the index date (without prescription in the 90 days period prior index date).
Study: NCT02314923

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V920 Vaccine
Description: Vesicular Stomatitis Virus (VSV)-based vaccine 1-mL injection containing 3x10\^3, 3x10\^4, 3x10\^5, 3x10\^6, 9x10\^6, 2x10\^7, or 1x10\^8 pfu.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V920 Vaccine
Description: Vesicular Stomatitis Virus (VSV)-based vaccine 1-mL injection containing 3x10\^3, 3x10\^4, 3x10\^5, 3x10\^6, 9x10\^6, 2x10\^7, or 1x10\^8 pfu.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V920 Vaccine
Description: Vesicular Stomatitis Virus (VSV)-based vaccine 1-mL injection containing 3x10\^3, 3x10\^4, 3x10\^5, 3x10\^6, 9x10\^6, 2x10\^7, or 1x10\^8 pfu.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V920 Vaccine
Description: Vesicular Stomatitis Virus (VSV)-based vaccine 1-mL injection containing 3x10\^3, 3x10\^4, 3x10\^5, 3x10\^6, 9x10\^6, 2x10\^7, or 1x10\^8 pfu.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V920 Vaccine
Description: Vesicular Stomatitis Virus (VSV)-based vaccine 1-mL injection containing 3x10\^3, 3x10\^4, 3x10\^5, 3x10\^6, 9x10\^6, 2x10\^7, or 1x10\^8 pfu.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V920 Vaccine
Description: Vesicular Stomatitis Virus (VSV)-based vaccine 1-mL injection containing 3x10\^3, 3x10\^4, 3x10\^5, 3x10\^6, 9x10\^6, 2x10\^7, or 1x10\^8 pfu.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V920 Vaccine
Description: Vesicular Stomatitis Virus (VSV)-based vaccine 1-mL injection containing 3x10\^3, 3x10\^4, 3x10\^5, 3x10\^6, 9x10\^6, 2x10\^7, or 1x10\^8 pfu.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V920 Vaccine
Description: Vesicular Stomatitis Virus (VSV)-based vaccine 1-mL injection containing 3x10\^3, 3x10\^4, 3x10\^5, 3x10\^6, 9x10\^6, 2x10\^7, or 1x10\^8 pfu.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.9% Saline

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.9% Saline
Study: NCT01651208

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing (MINT)
Description: We will hire a Latino and an AA nurse to deliver the interventions and will match their race/ethnicity with that of the subject. Past experience suggests that at 4-7 calls per subjects each lasting about 30-45 minutes, a nurse can carry a caseload of about 125-150 subject (we propose 125 per nurse) Each telephone encounter will have a patient centered approach having the following basic structure and goals:~a)Establishing a connection and reinforcing autonomy b)Empathizing with ambivalence and rolling with resistance.c)Coach the subject towards expressions of commitment.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mailed DVD
Description: The DVD will have a documentary format that will engage subjects as the portrayed real patients relate their struggles and successes, that will entertain and ultimately motivate subjects to succeed in a similar way as the role models in the video. That personal connection will activate patients to address their own adherence issues and will show real life ways to deal with the health behaviors recommended post PCIS. Key concepts regarding adherence to medications and other behaviors will be imbedded in the story telling. The DVD will also feature a humanistic perspective of a cardiologist talking about his concerns for his patients that do not adhere to the antiplatelet therapy, the difficulties that his patients face, and the merit of the success stories he witnesses.
Study: NCT01232140

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CRP-guided antibiotic treatment
Description: If CRP\> 50 mg/l patients with AECOPD receive antibiotic treatment, whereas in those patients with CRP =\< 50 mg/l antibiotic treatment are withheld. This will be compared to the regular antibiotic treatment that has been advised by the GOLD strategy

Intervention type: OTHER
Group type: OTHER
Intervention: CRP-guided antibiotic treatment
Description: If CRP\> 50 mg/l patients with AECOPD receive antibiotic treatment, whereas in those patients with CRP =\< 50 mg/l antibiotic treatment are withheld. This will be compared to the regular antibiotic treatment that has been advised by the GOLD strategy
Study: NCT03988218

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: perceptive tests
Description: many tests are realized: a drawing of the interior of the body a heartbeat detection test an ischemia induction test many scales: Eating Attitude Test; Body Awareness Questionnaire; Body Shape Questionnaire; Hospital Anxiety and Depression; Questionnaire de Satisfaction Corporelle et de Perception Globale de Soi

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: perceptive tests
Description: many tests are realized: a drawing of the interior of the body a heartbeat detection test an ischemia induction test many scales: Eating Attitude Test; Body Awareness Questionnaire; Body Shape Questionnaire; Hospital Anxiety and Depression; Questionnaire de Satisfaction Corporelle et de Perception Globale de Soi
Study: NCT01807884

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Optimized oral care
Description: An optimization of the oropharyngeal suction procedure will include use of a subglottic drainage in a specified order: 1. subglottic suction, 1.oral suction followed by mouth care 3. subglottic suction 4. tracheal suction

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Routine oral care
Description: Oral suction followed by mouth care and tracheal suction without any subglottic suction
Study: NCT02987530

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dolutegravir
Description: Oral use, 50mg/day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Darunavir-cobicistat
Description: Oral use, 800-150mg/day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Emtricitabine-Tenofovir
Description: Oral use, Emtricititabine : 200mg/day Ténofovir : 245mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Emtricitabine-Tenofovir
Description: Oral use, Emtricititabine : 200mg/day Ténofovir : 245mg
Study: NCT02714127

Intervention type: OTHER
Intervention: Cervicovaginal lavage fluid collection
Description: During colposcopy, the cervicovaginal region is rinsed for 2 minutes with 50 ml acetic acid (5%). This fluid is not discarded like it is done usually, but the remaining lavage fluid (5% acetic acid containing cervicovaginal fluid) will be collected.

Intervention type: OTHER
Intervention: Cervicovaginal lavage fluid collection
Description: During colposcopy, the cervicovaginal region is rinsed for 2 minutes with 50 ml acetic acid (5%). This fluid is not discarded like it is done usually, but the remaining lavage fluid (5% acetic acid containing cervicovaginal fluid) will be collected.
Study: NCT03980964

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active NMES
Description: Daily home-based, mobile-app controlled, neuromuscular electrical stimulation (NMES) therapy

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Active NMES
Description: Daily home-based, mobile-app controlled, neuromuscular electrical stimulation (NMES) therapy
Study: NCT02947815

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clostridium Botulinum Toxin Type A

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clostridium Botulinum Toxin Type A
Study: NCT03832660

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Lifestyle
Description: A 4-month lifestyle intervention will consist of two integrated components i.e. physical activity and dietary supplementation with inorganic nitrate. The physical activity component aims to increase daily physical activity level by at least 2000 steps/day from baseline (e.g. walking for approximately 30 minutes), at least 5-7 days per week. The second component of the lifestyle intervention is a dietary supplementation with inorganic nitrate. A single dose of inorganic nitrate given in the form of concentrated nitrate-rich beetroot juice (NO3-, BEET IT Sport, James White Drinks Ltd., Ipswich, UK) containing 6 mmol of NO3- in 70 ml bottle.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sacubitril/Valsartan
Description: Angiotensin receptor neprilysin inhibitor Sacubitril / Valsartan: The treatment period begins on day 1 with initial dosing of sacubitril/valsartan, followed by uptitration every 2 to 4 weeks to the target dose of 97/103 mg twice daily. 3 doses of sacubitril/valsartan available throughout the study are 24/26 mg, 49/51 mg, and 97/103 mg, each taken by mouth twice daily. If the patient discontinues the study medication, the patient is advised to return to the clinic for an end-of-study visit. Patients undergo treatment for 4 months.
Study: NCT04157842

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: total hip replacement with subtrochanteral osteotomy
Description: applying subtrochanteral osteotomy during the operation to release the tension of vessels and nerve

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: total hip replacement with no osteotomy
Description: just total hip replacement
Study: NCT03450109

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY01005
Description: One gluteal IM injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zoladex
Description: One Subcutaneous injection in the abdominal wall
Study: NCT02943993

Intervention type: DRUG
Intervention: Edoxaban
Description: Prescribed according to approved label
Study: NCT03425604

Intervention type: PROCEDURE
Intervention: Intrauterine insemination

Intervention type: PROCEDURE
Intervention: Intrauterine insemination
Study: NCT01005992

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fractional laser treatment
Description: A complete treatment will consist in four laser sessions with a second-generation erbium-doped 1,550-nm fractional photothermolysis laser (Fraxel SR laser, Reliant Technologies Inc at 1-month intervals. Treatment will be delivered with a 15-mm tip and concomitant air-cooling system (Zimmer MedizinSystems, Irvine, CA). Fluence and treatment level will be registered on every session and will be adjusted according to patient tolerance.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard scar management
Description: The standard treated scar arm consists of a similar lesion in an equivalent location in the same patient or the half of a lesion that is suitable to be divided (size at least 4% body surface area). This arm will be managed only with standard burn treatment modalities.
Study: NCT04550416

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ProMark Information and Test Results
Description: Participants in the intervention arm will receive information (both print and webinar format) about ProMark in between Round 1 and Round 2 data collection, as well as appropriate ProMark test results for each of the vignette-based simulated patients that they care for in the second round of data collection.
Study: NCT02833350

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MTX
Description: Participants will receive stable background therapy of MTX 15-25 mg/week (oral or parenteral; for participants entering the trial on MTX doses 15 mg/week, doses as low as 7.5 mg/week are allowed only if there is clear documentation in the medical record that higher doses were not tolerated or that the dose of MTX is the highest acceptable dose based on local clinical practice guidelines).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: MTX
Description: Participants will receive stable background therapy of MTX 15-25 mg/week (oral or parenteral; for participants entering the trial on MTX doses 15 mg/week, doses as low as 7.5 mg/week are allowed only if there is clear documentation in the medical record that higher doses were not tolerated or that the dose of MTX is the highest acceptable dose based on local clinical practice guidelines).
Study: NCT03526003

Intervention type: DIAGNOSTIC_TEST
Intervention: Measurement of esophageal pressure
Description: Measurement of esophageal pressure during posture changes and pneumoperotoneum
Study: NCT01323257

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erythromycin
Description: 500 mg tablets three times a day for 6 days + 1 morning dose for 7th day (Trt B)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir
Description: 100 mg tablet once daily for 7 days (Trt E, F)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC435
Description: 150 mg capsule once daily for 7 days (Trt A, C, D)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darunavir
Description: 2 x 400 mg tablet once daily for 7 days (Trt E, F)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC435
Description: 50 mg capsule once daily for 7 days (Trt F)
Study: NCT02833350

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MTX
Description: Participants will receive stable background therapy of MTX 15-25 mg/week (oral or parenteral; for participants entering the trial on MTX doses 15 mg/week, doses as low as 7.5 mg/week are allowed only if there is clear documentation in the medical record that higher doses were not tolerated or that the dose of MTX is the highest acceptable dose based on local clinical practice guidelines).
Study: NCT01323257

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erythromycin
Description: 500 mg tablets three times a day for 7 days (Trt C)
Study: NCT01855542

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 0.9% normal saline
Description: In each group, patients received either 0.9% normal saline or plasmalyte solution until end of surgery.
Study: NCT02833350

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: MTX
Description: Participants will receive stable background therapy of MTX 15-25 mg/week (oral or parenteral; for participants entering the trial on MTX doses 15 mg/week, doses as low as 7.5 mg/week are allowed only if there is clear documentation in the medical record that higher doses were not tolerated or that the dose of MTX is the highest acceptable dose based on local clinical practice guidelines).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive placebo matched to adalimumab, subcutaneously Q2W and/or placebo matched to GDC-0853, orally once or twice daily for 12 weeks in Cohort 1 or 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive placebo matched to adalimumab, subcutaneously Q2W and/or placebo matched to GDC-0853, orally once or twice daily for 12 weeks in Cohort 1 or 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive placebo matched to adalimumab, subcutaneously Q2W and/or placebo matched to GDC-0853, orally once or twice daily for 12 weeks in Cohort 1 or 2.
Study: NCT01855542

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: plasmalyte
Description: In each group, patients received either 0.9% normal saline or plasmalyte solution until end of surgery.
Study: NCT02833350

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Participants will receive placebo matched to adalimumab, subcutaneously Q2W and/or placebo matched to GDC-0853, orally once or twice daily for 12 weeks in Cohort 1 or 2.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive placebo matched to adalimumab, subcutaneously Q2W and/or placebo matched to GDC-0853, orally once or twice daily for 12 weeks in Cohort 1 or 2.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive placebo matched to adalimumab, subcutaneously Q2W and/or placebo matched to GDC-0853, orally once or twice daily for 12 weeks in Cohort 1 or 2.
Study: NCT00570765

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo tablets were administered orally once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obeticholic Acid (OCA)
Description: Starting dose of 10 or 50 mg administered orally once daily, followed by dose titration planned from 10 mg to 25 mg to 50 mg once daily, which could be modified for safety and tolerability issues or to achieve adequate therapeutic response.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obeticholic Acid (OCA)
Description: Starting dose of 10 or 50 mg administered orally once daily, followed by dose titration planned from 10 mg to 25 mg to 50 mg once daily, which could be modified for safety and tolerability issues or to achieve adequate therapeutic response.
Study: NCT01402271

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: carboplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: paclitaxel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pazopanib hydrochloride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pazopanib hydrochloride

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Study: NCT02090309

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrocortisone
Description: 100 mg IV (in the vein) injection as a single bolus of hydrocortisone for the study group.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal saline 0.9%
Description: IV injection of 5 ml normal saline 0.9% as a single bolus.
Study: NCT04451889

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: miniprobe Alveoflex
Description: Alveoflex uses 488nm laser, generating real time moving images with an optical area of 600μm at a video frame rate of 12 images per second and a focus depth of 50μm
Study: NCT00109967

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rituximab
Description: 375 mg/m\^2 Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: temsirolimus
Description: 25 mg given IV
Study: NCT01343173

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib stop
Description: To stop imatinib after inclusion.